UBS O'Connor’s Fulcrum Therapeutics FULC Stock Holding History

UBS O'Connor’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-62,274	Closed	-$177K	–	606
2023 Q1	$177K	Buy	+62,274	New	+$558K	﹤0.01%	518

Other funds holding FULC

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS O'Connor's FULC Position: Q2 2023 in Review

UBS O'Connor sold out of Fulcrum Therapeutics (FULC) in Q2 2023, closing a stake of 62,274 shares — an estimated $177K sold.

UBS O'Connor first reported a position in FULC in Q1 2023 and held it in 1 quarter. The position peaked at $177K in Q1 2023. 88 funds tracked by Wall St. Rank hold FULC as of Q2 2023.

UBS O'Connor reported no remaining Fulcrum Therapeutics position as of Q2 2023 after selling out during the quarter.
UBS O'Connor sold 62,274 Fulcrum Therapeutics shares in Q2 2023, an estimated $177K.
UBS O'Connor first reported a position in Fulcrum Therapeutics in Q1 2023 and held it in 1 quarter.
UBS O'Connor's Fulcrum Therapeutics position peaked at $177K in Q1 2023.
88 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2023.

Based on UBS O'Connor's 13F filing for Q2 2023, filed 14 Aug 2023.